Skip to main content
Top
Published in: Virchows Archiv 1/2006

01-07-2006 | Original Article

Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma

Authors: Lilach Kleinberg, Vivi Ann Flørenes, Martina Skrede, Hiep Phuc Dong, Søren Nielsen, Michael T. McMaster, Jahn M. Nesland, Ie-Ming Shih, Ben Davidson

Published in: Virchows Archiv | Issue 1/2006

Login to get access

Abstract

The aim of the present study was to evaluate HLA-G expression in breast carcinoma and malignant mesothelioma (MM). Malignant breast carcinoma effusions (46) and corresponding solid tumors (39) and 104 MM (26 effusions, 78 solid tumors) were analyzed using immunohistochemistry (IHC). HLA-G protein and mRNA expression were further studied using immunoblotting (IB) and RT-PCR. HLA-ABC expression was analyzed using flow cytometry (FCM). IHC showed predominantly focal HLA-G expression in 12 of 46 (26%) breast carcinoma effusions and 16 of 39 (41%) solid lesions. In MM, 20 of 78 (26%) solid lesions and 14 of 26 (54%) effusions were focally HLA-G positive. Expression in MM was higher in effusions (p=0.008). IB showed more frequent HLA-G expression in MM compared with breast carcinoma effusions, while RT-PCR showed HLA-G mRNA expression in both tumors. FCM showed conserved HLA-ABC expression in 15 of 15 effusions. Breast cancer patients with HLA-G-positive tumor cells had shorter disease-free survival (mean 37 vs 85, median 25 vs 31 months), though not significantly (p=0.14). In conclusion, HLA-G is focally expressed in MM and breast carcinoma, while HLA-ABC expression is conserved. However, the up-regulated expression of HLA-G in MM effusions and its possible association with shorter disease-free survival in advanced stage of breast carcinoma suggest a possible role in immune response evasion in some tumors.
Literature
1.
go back to reference Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904–910PubMedCrossRef Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904–910PubMedCrossRef
2.
go back to reference Banerjee AK, Willetts I, Robertson JF, Blamey RW (1994) Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 20:33–36PubMed Banerjee AK, Willetts I, Robertson JF, Blamey RW (1994) Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 20:33–36PubMed
4.
go back to reference Brostjan C, Bellon T, Sobanov Y, Lopez-Botet M, Hofer E (2002) Differential expression of inhibitory and activating CD94/NKG2 receptors on NK cell clones. J Immunol Methods 264:109–119PubMedCrossRef Brostjan C, Bellon T, Sobanov Y, Lopez-Botet M, Hofer E (2002) Differential expression of inhibitory and activating CD94/NKG2 receptors on NK cell clones. J Immunol Methods 264:109–119PubMedCrossRef
5.
go back to reference Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B (2003) Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63:4107–4111PubMed Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B (2003) Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63:4107–4111PubMed
6.
go back to reference Bukur J, Malenica B, Huber C, Seliger B (2003) Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol 64:1081–1092PubMedCrossRef Bukur J, Malenica B, Huber C, Seliger B (2003) Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol 64:1081–1092PubMedCrossRef
7.
8.
go back to reference Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bjåmer A, Berner A (1999) Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies. Evaluation of five epithelial markers. Virchows Arch 435:43–49PubMedCrossRef Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bjåmer A, Berner A (1999) Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies. Evaluation of five epithelial markers. Virchows Arch 435:43–49PubMedCrossRef
9.
go back to reference Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A, Risberg B, Johansen P (2001) The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25:1405–1412PubMedCrossRef Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A, Risberg B, Johansen P (2001) The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25:1405–1412PubMedCrossRef
10.
go back to reference Davidson B, Dong HP, Berner A, Christensen J, Nielsen S, Johansen P, Bryne M, Asschenfeldt P, Risberg B (2002) Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Am J Clin Pathol 118:85–92PubMedCrossRef Davidson B, Dong HP, Berner A, Christensen J, Nielsen S, Johansen P, Bryne M, Asschenfeldt P, Risberg B (2002) Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Am J Clin Pathol 118:85–92PubMedCrossRef
11.
go back to reference Davidson B, Risberg R, Reich R, Berner A (2003) Effusion cytology in ovarian cancer—new molecular methods as aids to diagnosis and prognosis. Clin Lab Med 23:729–754PubMedCrossRef Davidson B, Risberg R, Reich R, Berner A (2003) Effusion cytology in ovarian cancer—new molecular methods as aids to diagnosis and prognosis. Clin Lab Med 23:729–754PubMedCrossRef
12.
go back to reference Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, Sert B, Bedrossian C (2004) Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 44:159–165PubMedCrossRef Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, Sert B, Bedrossian C (2004) Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 44:159–165PubMedCrossRef
13.
go back to reference Davidson B, Reich R, Lazarovici P, Flørenes VA, Nielsen S, Nesland JM (2004) Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83:119–128PubMedCrossRef Davidson B, Reich R, Lazarovici P, Flørenes VA, Nielsen S, Nesland JM (2004) Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83:119–128PubMedCrossRef
14.
go back to reference Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner A, Nielsen S, Ilan N, Vlodavsky I, Reich R (2004) Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 21:469–476PubMedCrossRef Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner A, Nielsen S, Ilan N, Vlodavsky I, Reich R (2004) Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 21:469–476PubMedCrossRef
15.
go back to reference Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R (2004) Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients—a novel model for tumor progression. Clin Cancer Res 10:7335–7346PubMedCrossRef Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R (2004) Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients—a novel model for tumor progression. Clin Cancer Res 10:7335–7346PubMedCrossRef
16.
go back to reference Davidson B, Bukholt Elstrand M, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IM (2005) HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 96:42–47PubMedCrossRef Davidson B, Bukholt Elstrand M, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IM (2005) HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 96:42–47PubMedCrossRef
17.
go back to reference Dieterich M, Goodman SN, Rojas-Corona RR, Emralino AB, Jimenez-Joseph D, Sherman ME (1994) Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol 38:945–952PubMed Dieterich M, Goodman SN, Rojas-Corona RR, Emralino AB, Jimenez-Joseph D, Sherman ME (1994) Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol 38:945–952PubMed
18.
go back to reference Dutta N, Majumder D, Gupta A, Mazumder DNG, Banerjee S (2005) Analysis of human lymphocyte antigen class I expression in gastric cancer by reverse transcriptase-polymerase chain reaction. Hum Immunol 66:164–169PubMedCrossRef Dutta N, Majumder D, Gupta A, Mazumder DNG, Banerjee S (2005) Analysis of human lymphocyte antigen class I expression in gastric cancer by reverse transcriptase-polymerase chain reaction. Hum Immunol 66:164–169PubMedCrossRef
19.
go back to reference Hausheer FH, Yarbro JW (1985) Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12:54–75PubMed Hausheer FH, Yarbro JW (1985) Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12:54–75PubMed
20.
go back to reference Hofmeister V, Weiss EH (2003) HLA-G modulates immune responses by diverse receptor interactions. Semin Cancer Biol 13:317–323PubMedCrossRef Hofmeister V, Weiss EH (2003) HLA-G modulates immune responses by diverse receptor interactions. Semin Cancer Biol 13:317–323PubMedCrossRef
21.
go back to reference Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, Caignard A, Paul P (2001) Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61:6838–6845PubMed Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, Caignard A, Paul P (2001) Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61:6838–6845PubMed
22.
go back to reference Ibrahim EC, Aractingi S, Allory Y, Borrini F, Dupuy A, Duvillard P, Carosella ED, Avril MF, Paul P (2004) Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer 108:243–250CrossRef Ibrahim EC, Aractingi S, Allory Y, Borrini F, Dupuy A, Duvillard P, Carosella ED, Avril MF, Paul P (2004) Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer 108:243–250CrossRef
23.
go back to reference Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM (2003) Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63:7167–7175PubMed Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM (2003) Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63:7167–7175PubMed
24.
go back to reference Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P (2002) Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196:266–274PubMedCrossRef Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P (2002) Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196:266–274PubMedCrossRef
25.
go back to reference Martinez-Moragon E, Aparicio J, Sanchis J, Menendez R, Cruz Rogado M, Sanchis F (1998) Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 65:108–113PubMedCrossRef Martinez-Moragon E, Aparicio J, Sanchis J, Menendez R, Cruz Rogado M, Sanchis F (1998) Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 65:108–113PubMedCrossRef
26.
go back to reference Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Florenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996) Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 56:5490–5498PubMed Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Florenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996) Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 56:5490–5498PubMed
27.
go back to reference Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Soderstrom K, Levitskaya J, Kiessling R (2002) IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110:1515–1523PubMed Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Soderstrom K, Levitskaya J, Kiessling R (2002) IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110:1515–1523PubMed
28.
go back to reference McMaster MT, Librach CL, Zhou Y, Lim KH, Janatpour MJ, DeMars R, Kovats S, Damsky C, Fisher SJ (1995) Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 154:3771–3778PubMed McMaster MT, Librach CL, Zhou Y, Lim KH, Janatpour MJ, DeMars R, Kovats S, Damsky C, Fisher SJ (1995) Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 154:3771–3778PubMed
29.
go back to reference McMaster M, Zhou Y, Shorter S, Kapasi K, Geraghty D, Lim KH, Fisher SJ (1998) HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. J Immunol 160:5922–5928PubMed McMaster M, Zhou Y, Shorter S, Kapasi K, Geraghty D, Lim KH, Fisher SJ (1998) HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. J Immunol 160:5922–5928PubMed
30.
go back to reference Moretta L, Biassoni R, Bottino C, Cantoni C, Pende D, Mingari MC, Moretta A (2002) Human NK cells and their receptors. Microbes Infect 4:1539–1544PubMedCrossRef Moretta L, Biassoni R, Bottino C, Cantoni C, Pende D, Mingari MC, Moretta A (2002) Human NK cells and their receptors. Microbes Infect 4:1539–1544PubMedCrossRef
31.
go back to reference Palmisano GL, Pistillo MP, Fardin P, Capanni P, Nicolo G, Salvi S, Spina B, Pasciucco G, Ferrara GB (2002) Analysis of HLA-G expression in breast cancer tissue. Hum Immunol 63:969–976PubMedCrossRef Palmisano GL, Pistillo MP, Fardin P, Capanni P, Nicolo G, Salvi S, Spina B, Pasciucco G, Ferrara GB (2002) Analysis of HLA-G expression in breast cancer tissue. Hum Immunol 63:969–976PubMedCrossRef
32.
go back to reference Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED (1998) HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 95:4510–4515PubMedCrossRef Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED (1998) HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 95:4510–4515PubMedCrossRef
33.
go back to reference Paul P, Cabestre FA, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, Mercier S, Avril MF, Dausset J, Guillet JG, Carosella ED (1999) Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 59:1954–1960PubMed Paul P, Cabestre FA, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, Mercier S, Avril MF, Dausset J, Guillet JG, Carosella ED (1999) Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 59:1954–1960PubMed
34.
go back to reference Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I, Pangault C, Onno M, Fauchet R, Martinez-Laso J, Morales P, Villena AA, Giacomini P, Natali PG, Frumento G, Ferrara GB, McMaster M, Fisher S, Schust D, Ferrone S, Dausset J, Geraghty D, Carosella ED (2000) HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol 61:1177–1195PubMedCrossRef Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I, Pangault C, Onno M, Fauchet R, Martinez-Laso J, Morales P, Villena AA, Giacomini P, Natali PG, Frumento G, Ferrara GB, McMaster M, Fisher S, Schust D, Ferrone S, Dausset J, Geraghty D, Carosella ED (2000) HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol 61:1177–1195PubMedCrossRef
35.
go back to reference Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F (1999) Expression of HLA-G in human tumors is not a frequent event. Int J Cancer 81:512–518PubMedCrossRef Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F (1999) Expression of HLA-G in human tumors is not a frequent event. Int J Cancer 81:512–518PubMedCrossRef
36.
go back to reference Singer G, Kurman RJ, McMaster M, Shih I-M (2002) HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 26:914–920PubMedCrossRef Singer G, Kurman RJ, McMaster M, Shih I-M (2002) HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 26:914–920PubMedCrossRef
37.
go back to reference Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardelmann E, Grosse-Wilde H, Cheng CC, Kurman RJ, Shih IM (2003) HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 9:4460–4464PubMed Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardelmann E, Grosse-Wilde H, Cheng CC, Kurman RJ, Shih IM (2003) HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 9:4460–4464PubMed
38.
go back to reference Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A (2001) Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 159:817–824PubMed Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A (2001) Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 159:817–824PubMed
39.
go back to reference Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R (2002) HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99:609–617PubMedCrossRef Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R (2002) HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99:609–617PubMedCrossRef
40.
go back to reference van der Ven K, Pfeiffer K, Skrablin S (2000) HLA-G polymorphisms and molecule function—questions and more questions—a review. Placenta 21(Suppl A):S86–S92PubMed van der Ven K, Pfeiffer K, Skrablin S (2000) HLA-G polymorphisms and molecule function—questions and more questions—a review. Placenta 21(Suppl A):S86–S92PubMed
41.
go back to reference van Ruth S, Baas P, Zoetmulder FAN (2003) Surgical treatment of malignant pleural mesothelioma. Chest 123:551–561PubMedCrossRef van Ruth S, Baas P, Zoetmulder FAN (2003) Surgical treatment of malignant pleural mesothelioma. Chest 123:551–561PubMedCrossRef
42.
go back to reference Wilkes JD, Fidias P, Vaickus L, Perez RP (1995) Malignancy-related pericardial effusion. 127 cases from the Roswell Park Center Institute. Cancer 76:1377–1387PubMedCrossRef Wilkes JD, Fidias P, Vaickus L, Perez RP (1995) Malignancy-related pericardial effusion. 127 cases from the Roswell Park Center Institute. Cancer 76:1377–1387PubMedCrossRef
Metadata
Title
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
Authors
Lilach Kleinberg
Vivi Ann Flørenes
Martina Skrede
Hiep Phuc Dong
Søren Nielsen
Michael T. McMaster
Jahn M. Nesland
Ie-Ming Shih
Ben Davidson
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 1/2006
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-005-0144-7

Other articles of this Issue 1/2006

Virchows Archiv 1/2006 Go to the issue